Autopsy report · NCT07152730

A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump

“The decision to terminate development activities was based on business needs and unrelated to any safety or efficacy concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Ferring Pharmaceuticals

Sponsor type

Industry

Conditions

Amenorrhea; Fertility; Infertility

Interventions

Lutrepulse

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
  “strategy terminates development, the decision is not due to any safety-related issues” (74% match in meaning)
• Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
  “Business decision not to continue development” (70% match in meaning)
• Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury
  “Based on a business decision unrelated to any safety concerns.” (68% match in meaning)
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
  “The development was stopped due to company's strategy consideration” (67% match in meaning)
• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
  “Business decision, not related to safety” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.